Clinical Trial Update: Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating montelukast for mild-to-moderate respiratory symptoms in long-COVID-19 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars

Drugs mentioned

• Montelukast (Montelukast)

Snippet

Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | Conditions: Covid19, SARS (Disease) | Phase 3 | Status: TERMINATED